Completed PHASE1 INTERVENTIONAL 2-arm NCT03076385

Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of H10N8 Antigen mRNA in Healthy Adult Subjects

Sponsor: ModernaTX, Inc.

Conditions Influenza

Interventions Placebo VAL-506440

Updated 9 times since 2017 Last updated: Apr 21, 2022 Started: Dec 31, 2015 Primary completion: Oct 31, 2018 Completion: Oct 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03076385, this PHASE1 trial focuses on Influenza and remains completed. Sponsored by ModernaTX, Inc., it has been updated 9 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — May 2022 [monthly]

Completed PHASE1
Feb 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jan 2019 — Feb 2019 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE1
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE1
Apr 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ModernaTX, Inc.

Data source: ModernaTX, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany